Ociperlimab is under clinical development by BeiGene and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Squamous Non-Small Cell Lung Cancer have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ociperlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ociperlimab overview
Ociperlimab (BGB-A1217) is under development for the treatment of solid tumors including end stage small-cell lung cancer, locally advanced and metastatic non-squamous non-small cell lung cancer, metastatic squamous non-small cell lung cancer, recurrent or metastatic HNSCC, gastric/ gastroesophageal adenocarcinoma, relapsed or refractory diffuse large B-cell lymphoma and unspecified indication. The drug candidate is a humanized, IgG1 monoclonal antibody against T cell immunoreceptor with Ig and ITIM domains (TIGIT). It was under development for the treatment of triple negative breast cancer, advanced hepatocellular carcinoma, cervical cancer, recurrent or metastatic esophageal squamous cell carcinoma.
BeiGene overview
BeiGene is a biotechnology company. It specializes in the development and commercialization of immuno-oncology medicines to treat cancers. The company offers Zanubrutinib, a small molecule inhibitor to treat various blood cancers and Sonrotoclax, a small molecule Bcl-2 inhibitor for treating chronic lymphocytic leukemia. BeiGene also provides Tislelizumab (BGB-A317), a monoclonal antibody targeting solid tumors and hematologic cancer; and Pamiparib (BGB-290) against solid tumor malignancies. The company has operations in the US, Australia, Germany, Spain, Canada, Switzerland and Italy. BeiGene is headquartered in the Cayman Islands.
For a complete picture of Ociperlimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
